KOSPIBiotech & Pharma004310

Hyundai Pharmaceutical

₩5,950▼ 1.00%2026-11-18 close
Market Cap
₩190.4B
Turnover
₩1.1B
Volume
190K
Shares out.
32M
PER
47.5×
PBR
1.5×
EPS
₩154
Dividend Yield
0.41%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩30 per share · Prices as of the 2026-11-18 close

01

Report overview

Earnings Turnaround Meets Policy-Driven Volatility

Hyundai Pharmaceutical has extended its operating-profit recovery into 2026 after turning profitable in 2025, even as policy-driven news on hair-loss treatment and abortion pill coverage continues to drive share-price swings.

  1. 1

    2025 revenue reached KRW 191.8 billion (up 9.1% year on year), with operating profit surging 2,200.3% to KRW 4.16 billion, marking a turnaround year.

  2. 2

    Third-quarter 2026 revenue of KRW 56.3 billion rose for a second straight quarter from the first-quarter 2026 trough and was up 9.1% year on year.

  3. 3

    Net profit attributable to controlling shareholders has risen for three consecutive quarters from the fourth-quarter 2025 low through the third quarter of 2026.

  4. 4

    Expansion of prescription drugs such as the dementia combination treatment Demduo lifted the pharmaceutical segment to 84.0% of cumulative nine-month 2026 revenue.

  5. 5

    Government policy discussions on national health insurance coverage for hair-loss treatment and on introducing the abortion pill mifepristone have been key drivers of share-price volatility.

02

Business structure

Hyundai Pharmaceutical was founded in 1965 and listed on the Korea Exchange in 1978, operating prescription and over-the-counter drugs alongside food and cosmetics businesses.

For the cumulative nine months through the third quarter of 2026, the pharmaceutical segment generated KRW 132.96 billion, or 84.0% of total sales, the largest share, followed by food at KRW 18.454 billion (11.7%) and cosmetics and rental/other at KRW 6.899 billion (4.4%).

Within pharmaceuticals, the dementia combination treatment Demduo, the dementia drug Tamirin, and the lipid-lowering drug Ezepheno are flagship products, while the hair-loss brand Mynoxyl is a key focus among over-the-counter items.

The food segment centers on the Miero Fiber brand, which has sold more than 2.1 billion bottles since its 1989 launch, with new variants such as Salt Lemon and a kids' line continuing to roll out.

The cosmetics business, launched in March 2021, runs the peptide-based skincare brand Lab:Cl and the scalp/hair-loss care brand Mynoxcel, expanding online and offline channels including an Olive Young listing in January 2026.

Production takes place at the company's Cheonan and Hapcheon plants in South Chungcheong and South Gyeongsang provinces, which ran at an average utilization rate of 97.1% for the nine months through the third quarter of 2026, with cumulative output of KRW 45.628 billion.

The pharmaceutical business focuses on wholesaler and pharmacy-oriented sales alongside hospital-centered marketing for specialty treatments, while the food division expands through a distributor network and online/offline marketing.

Within the pharmaceutical and biotech sector, the company is classified as a smaller player relative to larger peers in terms of revenue and profit scale.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩51.6B₩3.5B6.7%
2025Q4₩48.7B₩42,668,8870.1%
2026Q1₩46.5B₩2.5B5.4%
2026Q2₩55.6B₩1B1.8%
2026Q3₩56.3B₩2.4B4.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩162.7B₩8B-₩200M4.9%−0.2%109.3%
2023₩180.8B₩6.9B₩6.1B3.8%7.2%82.6%
2024₩175.7B₩200M-₩600M0.1%−0.7%97.8%
2025₩191.8B₩4.2B₩2.5B2.2%3.1%98.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-10-19

04

Earnings analysis

Annual revenue in 2025 reached KRW 191.8 billion, up 9.1% from KRW 175.7 billion in 2024, the largest figure among 2022-2025.

Operating profit plunged from KRW 7.97 billion in 2022 to KRW 6.93 billion in 2023 (down 13.1%) and KRW 181 million in 2024 (down 97.4%), before rebounding to KRW 4.16 billion in 2025, up 2,200.3% year on year.

The operating margin fell to 0.1% in 2024 before recovering to 2.2% in 2025, with the highest margin in the 2022-2025 span recorded in 2022 at 4.9%.

Net profit attributable to controlling shareholders swung from a loss of KRW 165 million in 2022 to a profit of KRW 6.12 billion in 2023, back to a loss of KRW 575 million in 2024, and then to a profit of KRW 2.52 billion in 2025.

Net income including non-controlling interests followed the same pattern: a loss of KRW 165 million in 2022, profit of KRW 6.12 billion in 2023, loss of KRW 575 million in 2024, and profit of KRW 2.52 billion in 2025.

Operating cash flow was positive at KRW 11.6 billion in 2022 but turned negative for three straight years at -KRW 4.55 billion in 2023, -KRW 2.37 billion in 2024 and -KRW 123 million in 2025, though the size of the outflow has gradually narrowed.

On a quarterly basis, revenue slowed from KRW 51.6 billion in the third quarter of 2025 to KRW 48.7 billion in the fourth quarter (down 5.5%) and KRW 46.5 billion in the first quarter of 2026 (down 4.7%), before rising to KRW 55.6 billion in the second quarter (up 19.7%) and KRW 56.3 billion in the third quarter of 2026 (up 1.2% quarter on quarter and 9.1% year on year), marking two consecutive quarters of growth from the first-quarter 2026 trough.

Quarterly operating profit fell from KRW 3.46 billion in the third quarter of 2025 to KRW 42.67 million in the fourth quarter, then rebounded to KRW 2.52 billion in the first quarter of 2026 (up 5,809.1%), eased to KRW 976 million in the second quarter (down 61.3%), and rose to KRW 2.44 billion in the third quarter of 2026 (up 149.9% quarter on quarter, down 29.4% year on year).

Net profit attributable to controlling shareholders bottomed at KRW 268 million in the fourth quarter of 2025 and rose for three straight quarters to KRW 420 million, KRW 1.21 billion and KRW 1.71 billion through the third quarter of 2026, with the trailing four-quarter total (fourth quarter 2025 through third quarter 2026) reaching KRW 3.61 billion.

The profit improvement has been attributed in part to expanded prescriptions of the dementia combination drug Demduo, which reportedly captured more than 60% share of the donepezil-memantine combination market by prescription value in its first year, while a 20.8% year-on-year reduction in first-half recurring R&D expenses was also cited as contributing to the operating-profit gain.

05

Industry analysis

The pharmaceutical industry is shaped simultaneously by rising demand for dementia and chronic-disease treatments amid an aging population and by government moves to expand insurance coverage.

In Korea's diabetes and obesity treatment markets, GLP-1 injectables currently hold the lead, but development of low-molecule oral treatments has emerged as a new area of industry focus, and Hyundai Pharmaceutical is advancing a phase 2b trial of HDNO-1605, a GPR40-agonist type 2 diabetes drug designed to reduce hypoglycemia risk as a potential first-in-class treatment.

Some industry observers note, however, that language describing global clinical trial status for this pipeline asset has progressively disappeared from company filings, leaving only a reference to domestic phase 2b IND approval, prompting interpretations that the licensing-out strategy may have narrowed toward a domestic focus.

In the hair-loss treatment segment, policy discussion has continued since the government directed a review of national health insurance coverage, and Hyundai Pharmaceutical holds a broad portfolio spanning topical treatments such as Mynoxyl solution and oral drugs including finasteride-based Minofesia and dutasteride-based Damodart.

In the abortion-pill segment, the company is reported to hold domestic rights to the mifepristone-misoprostol combination product, and while government discussions on regulatory arrangements are ongoing, actual approval and the start of prescriptions still require separate review and the establishment of usage guidelines.

In terms of competitive positioning, the scale gap versus large biotech and pharmaceutical companies such as Samsung Biologics and Celltrion remains wide, and according to a July 2026 compilation by a market data provider, the company ranked 60th in revenue and 67th in operating profit among 139 companies in the sector, placing it among smaller players.

Hyundai Pharmaceutical is thus in the midst of transitioning from a traditional over-the-counter player toward a prescription-drug-centered model, with company-specific policy news appearing to drive share-price swings more than broad industry trends.

06

Outlook

For fiscal 2026, the company laid out a strategy to improve operating efficiency and strengthen academic capabilities in the prescription-drug business, introduce new over-the-counter products, and enter new markets in food and cosmetics, with a target of double-digit revenue growth.

On the drug-development front, beyond HDNO-1605, the company is developing a SMARCA2 inhibitor as its lead oncology asset in the synthetic-lethality field, with a USP1 inhibitor as a follow-on program at an early stage.

Early in 2026 the company disposed of roughly KRW 61.2 billion worth of treasury shares through share swaps with Shin Poong Pharmaceutical, Daewha Pharmaceutical and Samil Pharmaceutical, stating that proceeds would be directed toward expanding its Cheonan plant and funding clinical trials for its type 2 diabetes drug candidate.

The cosmetics business has been expanding distribution in 2026 through channels such as Olive Young and the Costco online store to broaden its sales base.

For Mifegymiso, a third marketing-authorization application remains under review by the Ministry of Food and Drug Safety, and the Ministry of Health and Welfare has said it is preparing clinical practice guidelines and other usage standards in case of approval, meaning the review outcome and the finalization of usage standards will determine the timing of any actual prescription launch.

In dementia care, the company is using Demduo as a platform to expand its product lineup across central-nervous-system conditions including depression and Parkinson's disease.

Management has said it intends to strengthen a total-care strategy that considers not only CNS products but also patients' medication adherence and caregivers' burden.

07

Valuation

PER
47.5×
PBR
1.5×
ROE
3.5%
EPS
₩154
BPS
₩4,885
Dividend per share
₩30

Hyundai Pharmaceutical's share price has shown wide swings in 2026 as policy expectations around hair-loss and dementia treatments alternated with news flow on the abortion pill issue.

One media outlet assessed that during the early-February 2026 price surge the price-to-earnings ratio expanded to more than 500 times, indicating that the trading band at times moved well above typical pharmaceutical-sector averages.

On the earnings side, the continuation of quarterly profit improvement into 2026 following the 2025 turnaround has been cited as a basis for valuation support, but some analysis suggests cost reductions from advertising/marketing efficiency and the pruning of low-margin products outweighed revenue growth, leaving mixed views on the quality of the earnings recovery.

Dividend payouts have tended to run lower than some sector peers, and the sustainability of earnings improvement, rather than dividends, tends to be cited as the key variable for investment judgment.

Overall, valuation assessments appear to mix short-term supply-demand shifts tied to policy themes with medium-term judgments on whether profit improvement is structurally grounded in revenue growth.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-10-19

08

Bull factors

Shift Toward Prescription Drugs, Led by Demduo

The dementia combination drug Demduo quickly gained more than 60% prescription-value share of the donepezil-memantine combination market in its first year on the market.

Building on this, the company is pursuing a 'CNS total care' strategy to extend its central-nervous-system lineup into depression and Parkinson's disease.

The prescription-drug segment's 84.0% share of cumulative nine-month 2026 revenue underscores a clear shift away from the company's traditional over-the-counter-centered structure.

Profit Recovery Accompanied by Cost Efficiency

Operating profit surged 2,200.3% year on year in 2025, and the company has sustained quarterly profitability into 2026. Cost structure improvements accompanied this, including a 20.8% year-on-year reduction in first-half recurring R&D expenses.

Net profit attributable to controlling shareholders has also risen for three consecutive quarters from the fourth-quarter 2025 trough through the third quarter of 2026.

Potential New Revenue Streams Tied to Policy Themes

Government discussions continue after directives to review national health insurance coverage for hair-loss treatments and usage arrangements for the abortion pill mifepristone.

Hyundai Pharmaceutical holds a hair-loss treatment portfolio spanning topical and oral products and is reported to hold domestic rights to the Mifegymiso combination product. If these discussions translate into actual policy, they could potentially become new revenue sources.

09

Bear factors

Concerns Over Narrowing Scope of In-House Pipeline

HDNO-1605, the company's sole in-house drug candidate, previously had global clinical status mentioned in filings, but later reports have described only domestic phase 2b IND approval. Some industry observers interpret this as a narrowing of the licensing-out strategy toward a domestic focus. The fact that the pipeline effectively depends on a single in-house asset is also cited as a risk factor.

Quarter-to-Quarter Earnings Volatility

Operating profit has swung sharply on a quarterly basis, falling to KRW 42.67 million in the fourth quarter of 2025 before rebounding to KRW 2.52 billion in the first quarter of 2026.

Operating profit also fell 61.3% quarter on quarter in the second quarter of 2026, leading some to caution against assuming a stable improvement trend. This high earnings volatility is cited as a factor that reduces the predictability of quarterly results.

Uncertainty Over Whether Policy Themes Translate Into Earnings

Both the hair-loss insurance coverage review and the mifepristone introduction discussions remain unresolved, with further review and the establishment of usage standards still required before any actual implementation or prescriptions could begin.

Mifegymiso's marketing-authorization application has twice been previously withdrawn over supplementary-data issues, so the outcome of the third review is not assured. If policy expectations fail to translate into actual sales, theme-driven share-price volatility could recur.

10

Risk factors

Regulatory/Approval

Mifegymiso has gone through voluntary withdrawals or supplementary submissions twice since its initial 2021 application, with a third application now under review by the Ministry of Food and Drug Safety.

HDNO-1605 also remains at the phase 2b clinical stage, with further trials and approval procedures required before commercialization. The timing and outcome of regulatory reviews are variables largely outside the company's control.

Financial Structure

The debt-to-equity ratio rose from 82.6% in 2023 to 97.8% in 2024 and 98.8% in 2025. Operating cash flow registered net outflows for three consecutive years from 2023 through 2025, meaning the profit recovery has not yet fully translated into stronger cash generation.

While financial stability itself does not appear to be at an immediately severe level, cash-flow improvement warrants continued monitoring.

Competition/Industry

Compared with larger biotech and pharmaceutical companies, the company's smaller revenue and profit base could constrain the resources it can deploy toward R&D and marketing.

Competition in diabetes and obesity treatments is intensifying with large global players backed by GLP-1 injectables, and the possibility of falling behind in the race to develop low-molecule oral treatments cannot be ruled out.

Hair-loss and dementia treatments are also areas where numerous pharmaceutical companies compete on a product-by-product basis.

11

What to watch next

  1. Around February 2027 (expected)

    As a November fiscal year-end company, Hyundai Pharmaceutical is expected to file its regular business report for FY2025/26 (December 2025-November 2026), a point to check whether the annual revenue and operating-margin improvement trend has been sustained.

  2. Upon announcement of the Ministry of Food and Drug Safety's review of the third Mifegymiso application

    The outcome of the third Mifegymiso marketing-authorization review and the progress of the Ministry of Health and Welfare's usage-guideline preparations should be monitored.

  3. Upon release of additional HDNO-1605 phase 2b clinical data

    Progress on the phase 2b trial of the GPR40-agonist diabetes candidate HDNO-1605, whether additional data are disclosed, and whether references to licensing-out return to company filings should be tracked.

  4. Upon the government's follow-up announcement on hair-loss treatment insurance coverage review

    Any government follow-up action or specific timeline announcement on the review of national health insurance coverage for hair-loss treatments could affect sales of related products.

12

Overall view

Hyundai Pharmaceutical has shown signs of fundamental improvement, extending quarterly profit gains into 2026 after turning both operating profit and net profit attributable to controlling shareholders positive in 2025.

However, views differ on the sustainability of this improvement given that it reflects a mix of cost reductions and genuine revenue growth.

Concerns over the narrowing scope of the in-house drug candidate HDNO-1605, uncertainty surrounding the Mifegymiso approval review, a rising debt ratio, and multi-year negative operating cash flow are factors that warrant balanced attention.

At the same time, the shift toward prescription drugs centered on hair-loss and dementia treatments, the rapid market uptake of Demduo, and potential new revenue sources tied to policy issues are cited as positive factors.

Upcoming regular business reports, regulatory review outcomes, and the progress of HDNO-1605's clinical trials will be key indicators for gauging future performance and business direction.

This report is intended for informational purposes based on disclosed financial figures and publicly available news, and does not include a buy or sell recommendation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.investing.com
  2. comp.wisereport.co.kr
  3. medicaltimes.com
  4. financialpost.co.kr
  5. alphasquare.co.kr
  6. m.pharmstock.co.kr
  7. v.daum.net
  8. topstarnews.net
  9. catch.co.kr
  10. medipana.com
  11. markets.hankyung.com
  12. medipana.com
  13. kind.krx.co.kr
  14. medicaltimes.com
  15. hyundaipharm.co.kr
  16. biospectator.com
  17. hdpharm.co.kr
  18. judal.co.kr

Report written 2026-10-20 · Data as of 2026-10-19

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis